Outcome of patients with acute GVHD according to clinical or biological markers
. | . | Day 28 nonresponse . | Day 180 survival . | Day 180 nonrelapse mortality . | |||
---|---|---|---|---|---|---|---|
Variable . | N . | No. . | Estimate (95% CI) . | No.* . | Estimate (95% CI) . | No. . | Estimate (95% CI) . |
All patients | 204 | 66 | 32% (26-39) | 43 | 79% (74-85) | 32 | 16% (11-21) |
Initial liver GVHD | |||||||
No | 171 | 41 | 24% (18-31) | 22 | 87% (82-92) | 13 | 8% (4-12) |
Yes | 33 | 25 | 76% (58-89) | 21 | 36% (23-57) | 19 | 58% (39-73) |
Acute GVHD initial grade | |||||||
1–2 | 143 | 34 | 24% (17-32) | 19 | 87% (81-92) | 11 | 8% (4-13) |
3 | 61 | 32 | 52% (39-65) | 24 | 61% (50-74) | 21 | 34% (23-46) |
Age | |||||||
<50 y | 115 | 29 | 25% (18-34) | 18 | 87% (81-92) | 14 | 12% (7-19) |
≥50 y | 89 | 37 | 42% (31-53) | 25 | 61% (50-74) | 18 | 20% (13-29) |
Fever | |||||||
Yes | 91 | 38 | 42% (32-53) | 24 | 74% (65-83) | 11 | 10% (5-16) |
No | 113 | 28 | 25% (17-34) | 19 | 83% (77-90) | 21 | 23% (15-32) |
No. of clinical variables† | |||||||
0 | 49 | 8 | 16% (7-30) | 3 | 94% (87-100) | 1 | 2% (0-25) |
1 | 83 | 22 | 27% (17-37) | 15 | 82% (74-91) | 10 | 12% (6-20) |
2 | 58 | 23 | 40% (27-53) | 17 | 71% (60-83) | 13 | 22% (13-34) |
3 | 14 | 13 | 93% (66->99) | 8 | 43% (23-78) | 8 | 57% (27-79) |
ST2 | |||||||
High | 51 | 25 | 49% (35-63) | 22 | 57% (45-72) | 19 | 37% (24-50) |
Low | 153 | 41 | 27% (20-35) | 21 | 86% (81-92) | 13 | 8% (5-14) |
Panel 2 | |||||||
High | 73 | 30 | 41% (30-53) | 28 | 62% (51-74) | 22 | 30% (20-41) |
Low | 131 | 36 | 27% (20-36) | 15 | 89% (83-94) | 10 | 8% (4-13) |
Panel 3 | |||||||
High | 51 | 26 | 51% (37-65) | 22 | 57% (45-72) | 20 | 39% (26-52) |
Low | 153 | 40 | 26% (19-34) | 11 | 86% (81-92) | 12 | 8% (4-13) |
Panel 4 | |||||||
High | 51 | 28 | 55% (40-69) | 22 | 57% (45-72) | 19 | 37% (24-50) |
Low | 153 | 38 | 25% (18-32) | 21 | 86% (81-92) | 13 | 8% (5-14) |
Panel 6 | |||||||
High | 85 | 38 | 45% (34-56) | 30 | 65% (55-76) | 26 | 31% (21-41) |
Low | 119 | 28 | 24% (16-32) | 13 | 89% (84-95) | 6 | 5% (2-10) |
. | . | Day 28 nonresponse . | Day 180 survival . | Day 180 nonrelapse mortality . | |||
---|---|---|---|---|---|---|---|
Variable . | N . | No. . | Estimate (95% CI) . | No.* . | Estimate (95% CI) . | No. . | Estimate (95% CI) . |
All patients | 204 | 66 | 32% (26-39) | 43 | 79% (74-85) | 32 | 16% (11-21) |
Initial liver GVHD | |||||||
No | 171 | 41 | 24% (18-31) | 22 | 87% (82-92) | 13 | 8% (4-12) |
Yes | 33 | 25 | 76% (58-89) | 21 | 36% (23-57) | 19 | 58% (39-73) |
Acute GVHD initial grade | |||||||
1–2 | 143 | 34 | 24% (17-32) | 19 | 87% (81-92) | 11 | 8% (4-13) |
3 | 61 | 32 | 52% (39-65) | 24 | 61% (50-74) | 21 | 34% (23-46) |
Age | |||||||
<50 y | 115 | 29 | 25% (18-34) | 18 | 87% (81-92) | 14 | 12% (7-19) |
≥50 y | 89 | 37 | 42% (31-53) | 25 | 61% (50-74) | 18 | 20% (13-29) |
Fever | |||||||
Yes | 91 | 38 | 42% (32-53) | 24 | 74% (65-83) | 11 | 10% (5-16) |
No | 113 | 28 | 25% (17-34) | 19 | 83% (77-90) | 21 | 23% (15-32) |
No. of clinical variables† | |||||||
0 | 49 | 8 | 16% (7-30) | 3 | 94% (87-100) | 1 | 2% (0-25) |
1 | 83 | 22 | 27% (17-37) | 15 | 82% (74-91) | 10 | 12% (6-20) |
2 | 58 | 23 | 40% (27-53) | 17 | 71% (60-83) | 13 | 22% (13-34) |
3 | 14 | 13 | 93% (66->99) | 8 | 43% (23-78) | 8 | 57% (27-79) |
ST2 | |||||||
High | 51 | 25 | 49% (35-63) | 22 | 57% (45-72) | 19 | 37% (24-50) |
Low | 153 | 41 | 27% (20-35) | 21 | 86% (81-92) | 13 | 8% (5-14) |
Panel 2 | |||||||
High | 73 | 30 | 41% (30-53) | 28 | 62% (51-74) | 22 | 30% (20-41) |
Low | 131 | 36 | 27% (20-36) | 15 | 89% (83-94) | 10 | 8% (4-13) |
Panel 3 | |||||||
High | 51 | 26 | 51% (37-65) | 22 | 57% (45-72) | 20 | 39% (26-52) |
Low | 153 | 40 | 26% (19-34) | 11 | 86% (81-92) | 12 | 8% (4-13) |
Panel 4 | |||||||
High | 51 | 28 | 55% (40-69) | 22 | 57% (45-72) | 19 | 37% (24-50) |
Low | 153 | 38 | 25% (18-32) | 21 | 86% (81-92) | 13 | 8% (5-14) |
Panel 6 | |||||||
High | 85 | 38 | 45% (34-56) | 30 | 65% (55-76) | 26 | 31% (21-41) |
Low | 119 | 28 | 24% (16-32) | 13 | 89% (84-95) | 6 | 5% (2-10) |